In the latest session, Enfusion Inc (NYSE: ENFN) closed at $8.67 down -0.69% from its previous closing price of $8.73. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 676312 shares were traded. ENFN stock price reached its highest trading level at $8.90 during the session, while it also had its lowest trading level at $8.65.
Ratios:
For a deeper understanding of Enfusion Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 43.83. For the most recent quarter (mrq), Quick Ratio is recorded 3.79 and its Current Ratio is at 3.79. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 28, 2024, Downgraded its rating to Sell and sets its target price to $8 from $9 previously.
On January 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $11 to $9.
On November 07, 2023, UBS started tracking the stock assigning a Neutral rating and target price of $9.UBS initiated its Neutral rating on November 07, 2023, with a $9 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 10 when Somers Deirdre sold 1,770 shares for $8.65 per share. The transaction valued at 15,310 led to the insider holds 34,471 shares of the business.
Herring Bradley sold 2,090 shares of ENFN for $18,706 on Jan 09. The Chief Financial Officer now owns 211,600 shares after completing the transaction at $8.95 per share. On Jan 09, another insider, Movchan Oleg, who serves as the Chief Executive Officer of the company, sold 1,355 shares for $8.95 each. As a result, the insider received 12,127 and left with 269,954 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENFN now has a Market Capitalization of 770.68M and an Enterprise Value of 755.52M. As of this moment, Enfusion’s Price-to-Earnings (P/E) ratio for their current fiscal year is 192.24, and their Forward P/E ratio for the next fiscal year is 36.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.54 while its Price-to-Book (P/B) ratio in mrq is 15.08. Its current Enterprise Value per Revenue stands at 4.48 whereas that against EBITDA is 39.05.
Stock Price History:
Over the past 52 weeks, ENFN has reached a high of $12.00, while it has fallen to a 52-week low of $7.37. The 50-Day Moving Average of the stock is 8.94, while the 200-Day Moving Average is calculated to be 9.16.
Shares Statistics:
For the past three months, ENFN has traded an average of 289.27K shares per day and 361.71k over the past ten days. A total of 70.86M shares are outstanding, with a floating share count of 43.57M. Insiders hold about 50.61% of the company’s shares, while institutions hold 60.51% stake in the company. Shares short for ENFN as of Feb 15, 2024 were 1.75M with a Short Ratio of 6.06, compared to 1.68M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.99% and a Short% of Float of 3.78%.
Earnings Estimates
There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.03, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.05, with high estimates of $0.06 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.16 and $0.13 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.25, with 8 analysts recommending between $0.29 and $0.18.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $45.27M this quarter.It ranges from a high estimate of $47M to a low estimate of $44.45M. As of the current estimate, Enfusion Inc’s year-ago sales were $40.52M, an estimated increase of 11.70% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $46.79M, an increase of 12.60% over than the figure of $11.70% in the same quarter last year. There is a high estimate of $48M for the next quarter, whereas the lowest estimate is $45.39M.
A total of 8 analysts have provided revenue estimates for ENFN’s current fiscal year. The highest revenue estimate was $174.1M, while the lowest revenue estimate was $172.5M, resulting in an average revenue estimate of $173.28M. In the same quarter a year ago, actual revenue was $150.35M, up 15.30% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $202.3M in the next fiscal year. The high estimate is $210.5M and the low estimate is $199.03M. The average revenue growth estimate for next year is up 16.70% from the average revenue estimate for this year.
